Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient With MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.04.007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

EGFR T790M Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Lung Adenocarcinoma Patients With Acquired Resistance to First Generation EGFR Tyrosine Kinase Inhibitors

Diagnostic Pathology
Forensic MedicineMedicinePathologyHistology
2018English

A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition

OncoTargets and Therapy
OncologyPharmacology
2015English

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

Mechanisms of Acquired Resistance to EGFR-tyrosine Kinase Inhibitor in Korean Patients With Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2013English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy
OncologyPharmacology
2016English

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Cancer Research
Cancer ResearchOncology
2017English

Impressive Response to Tyrosine Kinase Inhibitors in a Patient With Respiratory Failure for EGFR -Mutated Metastatic Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

JAMA Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy